OCGN Ocugen, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1372299 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-1.3%
TTM net income YoY-24.7%
TTM EPS YoY-11.2%
Revenue 3-yr CAGR22.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,483.9%
Net margin-1,605.2%
FCF margin-1,334.3%
EBITDA margin-1,430.1%
Returns
ROE-660.0%
ROA-118.1%
ROIC (approx.)-1,221.1%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets89.8%
Debt / equity5.03x
Current ratio1.86x
Interest coverage-12.62x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue3.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.41M | $4.05M |
| R&D expense | $39.75M | $32.13M |
| SG&A expense | $27.58M | $26.69M |
| Operating income | -$62.92M | -$54.76M |
| Interest expense | $5.19M | $688,000 |
| Pretax income | -$67.85M | -$54.05M |
| Income tax | $0 | $0 |
| Net income | -$67.85M | -$54.05M |
| EBITDA | -$60.52M | -$52.86M |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $18.57M | $58.82M |
| Short-term investments | $0 | — |
| Current assets | $24.34M | $61.68M |
| PP&E, net | $14.39M | $16.55M |
| Total assets | $43.52M | $82.44M |
| Current liabilities | $23.04M | $21.59M |
| Short-term debt | $1.25M | $1.33M |
| Long-term debt | $27.54M | $27.34M |
| Total debt | $28.79M | $28.67M |
| Total liabilities | $55.68M | $52.81M |
| Shareholders' equity | -$12.17M | $29.63M |
| Net debt | $10.22M | -$30.15M |
| Shares outstanding | 312.38M | 291.37M |
| Cash flow statement | ||
| Operating cash flow | -$56.96M | -$42.14M |
| Capital expenditure | $185,000 | $3.38M |
| Free cash flow | -$57.15M | -$45.53M |
| Investing cash flow | -$311,000 | -$3.38M |
| Financing cash flow | $17.33M | $64.86M |
| Depreciation & amortization | $2.40M | $1.90M |
| Stock-based compensation | $7.71M | $7.43M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.